Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Cutler

Showing results (181-190 of 217) with videos related to

Pageof 22
Sort By:
Pharmaceutics|October 27, 2022
Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I ResultsJin-Bon Hong, Po-Yuan Wu, Albert Qin, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2002
Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumoursA Awada, F A L M Eskens, M Piccart, et al.
International Journal of Clinical Pharmacology and Therapeutics|August 21, 2014
Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjectsXia Chen, Teddy Kosoglou, Paul Statkevich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumorsF A Eskens, A Awada, D L Cutler, et al.
British Journal of Clinical Pharmacology|September 19, 2002
Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatinTeddy Kosoglou, Ingo Meyer, Enrico P Veltri, et al.
British Journal of Pharmacology|April 18, 2009
Inhibition of colonic motility and defecation by RS-127445 suggests an involvement of the 5-HT2B receptor in rodent large bowel physiologyA K Bassil, C M Taylor, V J N Bolton, et al.
British Journal of Cancer|April 3, 2003
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedulesA W Tolcher, S L Gerson, L Denis, et al.
Journal of Medicinal Chemistry|April 5, 2018
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361)Michael P Smolinski, Yahao Bu, James Clements, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 15, 1997
Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administrationD Pajkrt, L Camoglio, M C Tiel-van Buul, et al.
Cancer Research|April 15, 2000
A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activityA A Adjei, C Erlichman, J N Davis, et al.
Pageof 22

Showing results (181-190 of 217) with videos related to

Sort By:
Pageof 22
Pharmaceutics|October 27, 2022
Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I ResultsJin-Bon Hong, Po-Yuan Wu, Albert Qin, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2002
Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumoursA Awada, F A L M Eskens, M Piccart, et al.
International Journal of Clinical Pharmacology and Therapeutics|August 21, 2014
Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjectsXia Chen, Teddy Kosoglou, Paul Statkevich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumorsF A Eskens, A Awada, D L Cutler, et al.
British Journal of Clinical Pharmacology|September 19, 2002
Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatinTeddy Kosoglou, Ingo Meyer, Enrico P Veltri, et al.
British Journal of Pharmacology|April 18, 2009
Inhibition of colonic motility and defecation by RS-127445 suggests an involvement of the 5-HT2B receptor in rodent large bowel physiologyA K Bassil, C M Taylor, V J N Bolton, et al.
British Journal of Cancer|April 3, 2003
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedulesA W Tolcher, S L Gerson, L Denis, et al.
Journal of Medicinal Chemistry|April 5, 2018
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361)Michael P Smolinski, Yahao Bu, James Clements, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 15, 1997
Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administrationD Pajkrt, L Camoglio, M C Tiel-van Buul, et al.
Cancer Research|April 15, 2000
A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activityA A Adjei, C Erlichman, J N Davis, et al.
Pageof 22